Last reviewed · How we verify
NBF
NBF is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
NBF is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | NBF |
|---|---|
| Sponsor | Universidad Complutense de Madrid |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, NBF reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- The Effectiveness of Nano Bio Fusion Gingival Gel (NBF) on Wound Healing at the Palate (Donor Site) After Soft Tissue Graft Surgery Compared to Placebo Gel. (NA)
- Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA). (PHASE4)
- Effect of Nano-Bio Fusion Gel on Palatal Wound Healing After Free Gingival Graft Harvest. (PHASE4)
- A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer (PHASE1)
- Conscious Movement Processing, Postural Stability and Muscle Efficiency in Older Adults
- Effects of 8-weeks Systematic Corrective Exercise Program in Pronation Distortion Syndrome (NA)
- Effect of Oxidant Gel and Anti-oxidant Gel on Wound Healing After Gingival Depigmentation (PHASE4)
- NBF Gingival Gel Application After Impacted Lower Third Molar Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBF CI brief — competitive landscape report
- NBF updates RSS · CI watch RSS
- Universidad Complutense de Madrid portfolio CI